Lipid measures and cardiovascular disease prediction

Disease Markers

Volumn 26, Issue 5-6, 2009, Pages 209-216

  Van Wijk, Diederik F ^a   Stroes, Erik S G ^a   Kastelein, John J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Apolipoprotein B A I ratio; Atherosclerosis; Cardiovascular disease; HDL cholesterol; LDL cholesterol; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; LIPID ANALYSIS; LIPID METABOLISM; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 70349907364     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2009-0636     Document Type: Review

References (67)

1. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto, Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson and R.J. Glynn, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med 359 (2008), 2195-2207.
2. C.L. Yen, S.J. Stone, S. Koliwad, C. Harris and R.V. Farese, Jr., Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis, J Lipid Res 49 (2008), 2283-2301.
3. K.J. Williams, Molecular processes that handle - and mishandle - dietary lipids, J Clin Invest 118 (2008), 3247-3259.
4. T. Twickler, G.M. linga-Thie, M.J. Chapman and J.S. Cohn, Remnant lipoproteins and atherosclerosis, Curr Atheroscler Rep 7 (2005), 140-147.
5. S.O. Olofsson, P. Stillemark-Billton and L. Asp, Intracellular assembly of VLDL: two major steps in separate cell compartments, Trends Cardiovasc Med 10 (2000), 338-345.
6. M. Adiels, S.O. Olofsson, M.R. Taskinen and J. Boren, Over-production of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome, Arterioscler Thromb Vasc Biol 28 (2008), 1225-1236.
7. R.W. Mahley and T.P. Bersot, High density lipoprotein cholesterol in coronary artery patients: is it as low as expected? Anadolu Kardiyol Derg 6 (2006), 94-96.
8. R.W. Mahley, Y. Huang and K.H. Weisgraber, Putting cholesterol in its place: apoE and reverse cholesterol transport, J Clin Invest 116 (2006), 1226-1229.
9. K. Imaizumi, R.J. Havel, M. Fainaru and J.L. Vigne, Origin and transport of the A-I and arginine-rich apolipoproteins in mesenteric lymph of rats, J Lipid Res 19 (1978), 1038-1046.
10. E.J. Schaefer, C.B. Blum, R.I. Levy, L.L. Jenkins, P. Alaupovic, D.M. Foster and H.B. Brewer, Jr., Metabolism of high-density lipoprotein apolipoproteins in Tangier disease, N Engl J Med 299 (1978), 905-910. (Pubitemid 9050455)
11. N. Wang, D.L. Silver, C. Thiele and A.R. Tall, ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein, J Biol Chem 276 (2001), 23742-23747. (Pubitemid 37410769)
12. V.I. Zannis, A. Chroni and M. Krieger, Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL, J Mol Med 84 (2006), 276-294.
13. A.J. Lusis, Atherosclerosis, Nature 407 (2000), 233-241.
14. D.J. Rader and A. Daugherty, Translating molecular discoveries into new therapies for atherosclerosis, Nature 451 (2008), 904-913. (Pubitemid 351301745)
15. A. KAGAN, T.R. Dawber, W.B. Kannel and N. Revotskie, The Framingham study: a prospective study of coronary heart disease, Fed Proc 21(4 Pt 2) (1962), 52-57.
16. The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease, JAMA 235 (1976), 825-827.
17. The coronary primary prevention trial: design and implementation: the Lipid Research Clinics Program, J Chronic Dis 32 (1979), 609-631.
18. J. Stamler, M.L. Daviglus, D.B. Garside, A.R. Dyer, P. Greenland and J.D. Neaton, Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity, JAMA 284 (2000), 311-318.
19. H. Mabuchi, S. Miyamoto, K. Ueda, M. Oota, T. Takegoshi, T. Wakasugi and R. Takeda, Causes of death in patients with familial hypercholesterolemia, Atherosclerosis 61 (1986), 1-6. (Pubitemid 16098884)
20. C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins and R. Simes, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet 366 (2005), 1267-1278.
21. R.M. Krauss, F.T. Lindgren, P.T. Williams, S.F. Kelsey, J. Brensike, K. Vranizan, K.M. Detre and R.I. Levy, Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men, Lancet 2 (1987), 62-66.
22. K. Kugiyama, H. Doi, K. Takazoe, H. Kawano, H. Soejima, Y. Mizuno, R. Tsunoda, T. Sakamoto, T. Nakano, K. Nakajima, H. Ogawa, S. Sugiyama, M. Yoshimura and H. Yasue, Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease, Circulation 99 (1999), 2858-2860. (Pubitemid 29258971)
23. H. Fukushima, K. Kugiyama, S. Sugiyama, O. Honda, S. Koide, S. Nakamura, H. Kawano, H. Soejima, S. Miyamoto, M. Yoshimura, T. Sakamoto and H. Ogawa, Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease, Am J Cardiol 88 (2001), 1370-1373. (Pubitemid 34008679)
24. H. Masuoka, S. Kamei, H. Wagayama, M. Ozaki, A. Kawasaki, T. Tanaka, M. Kitamura, S. Katoh, U. Shintani, M. Misaki, M. Sugawa, M. Ito and T. Nakano, Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels, Am Heart J 139 (2000), 305-310. (Pubitemid 30090808)
25. H.N. Hodis, W.J. Mack, M. Dunn, C. Liu, C. Liu, R.H. Selzer and R.M. Krauss, Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness, Circulation 95 (1997), 2022-2026. (Pubitemid 27184268)
26. H.K. El, W.A. van der Steeg, E.S. Stroes, J.A. Kuivenhoven, J.D. Otvos, N.J. Wareham, B.A. Hutten, J.J. Kastelein, K.T. Khaw and S.M. Boekholdt, Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study, J Am Coll Cardiol 49 (2007), 547-553. (Pubitemid 46177441)
27. R.C. Pasternak, S.C. Smith, Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman and C. Lenfant, ACC/AHA/NHLBI clinical advisory on the use and safety of statins, J AmColl Cardiol 40 (2002), 567-572. (Pubitemid 34833176)
28. M.R. Law and N.J. Wald, Risk factor thresholds: their existence under scrutiny, BMJ 324 (2002), 1570-1576.
29. Y.L. Marcel, M. Ouimet and M.D. Wang, Regulation of cholesterol efflux from macrophages, Curr Opin Lipidol 19 (2008), 455-461.
30. D.F. van Wijk, E.S. Stroes and H. Monajemi, Changing paradigm in HDL metabolism and cellular effects, Clinical lipidology 4 (2009), 17-27.
31. B.J. Ansell, G.C. Fonarow and A.M. Fogelman, The paradox of dysfunctional high-density lipoprotein, Curr Opin Lipidol 18 (2007), 427-434.
32. M. Navab, S.Y. Hama, G.P. Hough, G. Subbanagounder, S.T. Reddy and A.M. Fogelman, A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids, J Lipid Res 42 (2001), 1308-1317.
33. M. Navab, S. Reddy, B.J. Van Lenten, G.M. Anantharamaiah and A.M. Fogelman, Role of dysfunctional HDL in atherosclerosis, J Lipid Res (2008).
34. M. Navab, G.M. Ananthramaiah, S.T. Reddy, B.J. Van Lenten, B.J. Ansell, S. Hama, G. Hough, E. Bachini, V.R. Grijalva, A.C. Wagner, Z. Shaposhnik and A.M. Fogelman, The double jeopardy of HDL, Ann Med 37 (2005), 173-178.
35. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel and T.R. Dawber, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study, Am J Med 62 (1977), 707-714. (Pubitemid 8110784)
36. G. Assmann and H. Schulte, Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study, Am J Cardiol 70 (1992), 733-737.
37. F.M. Sacks, A.M. Tonkin, T. Craven, M.A. Pfeffer, J. Shepherd, A. Keech, C.D. Furberg and E. Braunwald, Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors, Circulation 105 (2002), 1424-1428.
38. P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, S.M. Grundy, J.J. Kastelein, V. Bittner and J.C. Fruchart, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events, N Engl J Med 357 (2007), 1301-1310. (Pubitemid 47481452)
39. G. Assmann, H. Schulte, H. Funke and E.A. von, The emergence of triglycerides as a significant independent risk factor in coronary artery disease, Eur Heart J 19 Suppl M (1998), M8-M14. (Pubitemid 28470458)
40. J. Jeppesen, H.O. Hein, P. Suadicani and F. Gyntelberg, Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study, Circulation 97 (1998), 1029-1036. (Pubitemid 28145372)
41. M. bdel-Maksoud, V. Sazonov, S.W. Gutkin and J.E. Hokanson, Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes, J Cardiovasc Pharmacol 51 (2008), 331-351.
42. N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, S.M. Boekholdt, K.T. Khaw and V. Gudnason, Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies, Circulation 115 (2007), 450-458.
43. J.E. Hokanson and M.A. Austin, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies, J Cardiovasc Risk 3 (1996), 213-219.
44. A. Tirosh, A. Rudich, T. Shochat, D. Tekes-Manova, E. Israeli, Y. Henkin, I.Kochba and I. Shai, Changes in triglyceride levels and risk for coronary heart disease in young men, Ann Intern Med 147 (2007), 377-385. (Pubitemid 351664538)
45. E.M. von, A. Hamann, D. Twardella, P.P. Nawroth, H. Brenner and D. Rothenbacher, Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease, Eur Heart J 29 (2008), 1307-1315.
46. B.G. Nordestgaard, M. Benn, P. Schnohr and A. Tybjaerg-Hansen, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA 298 (2007), 299-308. (Pubitemid 47080484)
47. S. Bansal, J.E. Buring, N. Rifai, S. Mora, F.M. Sacks and P.M. Ridker, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women, JAMA 298 (2007), 309-316. (Pubitemid 47080485)
48. A. Langsted, J.J. Freiberg and B.G. Nordestgaard, Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction, Circulation 118 (2008), 2047-2056.
49. S. Mora, N. Rifai, J.E. Buring and P.M. Ridker, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events, Circulation 118 (2008), 993-1001.
50. G. Walldius and I. Jungner, Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy, J. Intern. Med. 255 (2004), 188-205.
51. B. Lamarche, A. Tchernof, S. Moorjani, B. Cantin, G.R. Dagenais, P.J. Lupien and J.P. Despres, Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study, Circulation 95 (1997), 69-75. (Pubitemid 27029945)
52. A.C. St-Pierre, I.L. Ruel, B. Cantin, G.R. Dagenais, P.M. Bernard, J.P. Despres and B. Lamarche, Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease, Circulation 104 (2001), 2295-2299.
53. J.Y. Lee and J.S. Parks, ATP-binding cassette transporter AI and its role in HDL formation, Curr Opin Lipidol 16 (2005), 19-25.
54. C.J. Fielding, V.G. Shore and P.E. Fielding, Lecithin: cholesterol acyltransferase: effects of substrate composition upon enzyme activity, Biochim. Biophys. Acta 270 (1972), 513-518.
55. M. Navab, S.Y. Hama, G.M. Anantharamaiah, K. Hassan, G.P. Hough, A.D. Watson, S.T. Reddy, A. Sevanian, G.C. Fonarow and A.M. Fogelman, Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3, J Lipid Res 41 (2000), 1495-1508. (Pubitemid 30743599)
56. S.M. Marcovina, J.J. Albers, L.O. Henderson and W.H. Hannon, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material, Clin Chem 39 (1993), 773-781. (Pubitemid 23145664)
57. S.M. Marcovina, J.J. Albers, H. Kennedy, J.V. Mei, L.O. Henderson and W.H. Hannon, International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material, Clin Chem 40 (1994), 586-592. (Pubitemid 24116108)
58. G. Walldius, I. Jungner, I. Holme, A.H. Aastveit, W. Kolar and E. Steiner, High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study, Lancet 358 (2001), 2026-2033.
59. S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos and L. Lisheng, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet 364 (2004), 937-952. (Pubitemid 39208455)
60. G. Luc, J.M. Bard, J. Ferrieres, A. Evans, P. Amouyel, D. Arveiler, J.C. Fruchart and P. Ducimetiere, Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction, Arterioscler Thromb Vasc Biol 22 (2002), 1155-1161.
61. A.R. Sharrett, C.M. Ballantyne, S.A. Coady, G. Heiss, P.D. Sorlie, D. Catellier and W. Patsch, Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study, Circulation 104 (2001), 1108-1113.
62. P.M. Ridker, N. Rifai, N.R. Cook, G. Bradwin and J.E. Burning, Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women, JAMA 294 (2005), 326-333.
63. E. Ingelsson, E.J. Schaefer, J.H. Contois, J.R. McNamara, L. Sullivan, M.J. Keyes, M.J. Pencina, C. Schoonmaker, P.W. Wilson, R.B. D'Agostino and R.S. Vasan, Clinical utility of different lipid measures for prediction of coronary heart disease in men and women, JAMA 298 (2007), 776-785. (Pubitemid 47263160)
64. W.A. van der Steeg, S.M. Boekholdt, E.A. Stein, K. El-Harchaoui, E.S. Stroes, M.S. Sandhu, N.J. Wareham, J.W. Jukema, R. Luben, A.H. Zwinderman, J.J. Kastelein and K.T. Khaw, Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk, Ann Intern Med 146 (2007), 640-648.
65. B. Zethelius, L. Berglund, J. Sundstrom, E. Ingelsson, S. Basu, A. Larsson, P.Venge and J. Arnlov, Use of multiple biomarkers to improve the prediction of death from cardiovascular causes, N Engl J Med 358 (2008), 2107-2116.
66. N.R. Cook, J.E. Buring and P.M. Ridker, The effect of including C-reactive protein in cardiovascular risk prediction models for women, Ann Intern Med 145 (2006), 21-29. (Pubitemid 46780601)
67. K.K. Ray, C.P. Cannon, R. Cairns, D.A. Morrow, P.M. Ridker and E. Braunwald, Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22, Arterioscler Thromb Vasc Biol 29 (2009), 424-430.